Purchase this article with an account.
C. Klaas, J. Clever, H. Hsu, T. Lily, L. Akduman; Effect of Nepafenac vs. Bromfenac on OCT Measured Macular Thickness After Cataract Surgery. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1378.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate changes in macular thickness after cataract surgery in patients randomized to nepafenac versus bromfenac or control.
Twenty-six patients (27 eyes) were prospectively randomized to topical nepafenac, bromfenac or control for post cataract surgery management. Nepafenac or bromfenac were started 1 hour prior to surgery and continued for one month. The control group did not receive nonsteroidal anti-inflammatory (NSAID) drops. All patients underwent uncomplicated cataract surgery and did not have any associated ocular or systemic disorders known to influence macular thickness. All study patients used the same regimen of prednisolone acetate concomitantly. Central foveal thickness (CFT) measured with OCT was used to determine macular thickness preoperatively and 1 month postoperatively.
Ten patients (11 eyes) completed 1 month follow up with all the data available. Four eyes received nepafenac, 4 received bromfenac, and 3 were randomized to the control group. Preoperative CFT was 215 +/- 31 microns for nepafenac, 174 +/- 28 for bromfenac, and 197 +/- 20 for the control group. Postoperative CFT was 216 +/- 26 microns for nepafenac, 215 +/- 24 for bromfenac, and 226 +/- 41 for the control group. A comparison was performed using an independent t-test. There was no statistically significant difference in CFT between the nepafenac, bromfenac, and control groups.
There was no difference in CFT changes postoperatively in patients receiving nepafenac, bromfenac or no NSAID as part of their post-operative care. Choice of topical NSAID as part of cataract surgery management should not depend on their effect on macular thickness changes.
This PDF is available to Subscribers Only